- Home
- ZENV vs BMEA Comparison
ZENV vs BMEA Comparison
Compare ZENV & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- BMEA
- Stock Information
- Founded
- ZENV 2005
- BMEA 2017
- Country
- ZENV Brazil
- BMEA United States
- Employees
- ZENV N/A
- BMEA N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- BMEA Health Care
- Exchange
- ZENV Nasdaq
- BMEA Nasdaq
- Market Cap
- ZENV 79.2M
- BMEA 65.8M
- IPO Year
- ZENV 2021
- BMEA 2021
- Fundamental
- Price
- ZENV $1.49
- BMEA $1.67
- Analyst Decision
- ZENV
- BMEA Strong Buy
- Analyst Count
- ZENV 0
- BMEA 10
- Target Price
- ZENV N/A
- BMEA $22.30
- AVG Volume (30 Days)
- ZENV 87.2K
- BMEA 2.3M
- Earning Date
- ZENV 07-02-2025
- BMEA 07-30-2025
- Dividend Yield
- ZENV N/A
- BMEA N/A
- EPS Growth
- ZENV N/A
- BMEA N/A
- EPS
- ZENV N/A
- BMEA N/A
- Revenue
- ZENV $181,911,572.00
- BMEA N/A
- Revenue This Year
- ZENV $8.58
- BMEA N/A
- Revenue Next Year
- ZENV $8.83
- BMEA N/A
- P/E Ratio
- ZENV N/A
- BMEA N/A
- Revenue Growth
- ZENV 23.99
- BMEA N/A
- 52 Week Low
- ZENV $1.02
- BMEA $1.29
- 52 Week High
- ZENV $3.03
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- ZENV 44.62
- BMEA 42.36
- Support Level
- ZENV $1.45
- BMEA $1.63
- Resistance Level
- ZENV $1.59
- BMEA $3.08
- Average True Range (ATR)
- ZENV 0.16
- BMEA 0.23
- MACD
- ZENV -0.01
- BMEA -0.08
- Stochastic Oscillator
- ZENV 16.96
- BMEA 5.33
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.